{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:46:00Z","timestamp":1793702760987,"version":"4.5.1"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Biomarkers may have a diagnostic or monitoring value, or may predict response to therapy or disease course. The aim of this review is to discuss new serum and urinary biomarkers recently proposed for the diagnosis and management of SLE patients. Novel sensitive and specific assays have been proposed to evaluate complement proteins, \u2018old\u2019 biomarkers that are still a cornerstone in the management of this disease. Chemokines and lectins have been evaluated as surrogate biomarkers of IFN signature. Other cytokines like the B cell activating factor (BAFF) family cytokines are directly related to perturbations of the B cell compartment as key pathogenetic mechanism of the disease. A large number of urine biomarkers have been proposed, either related to the migration and homing of leukocytes to the kidney or to the local regulation of inflammatory circuits and the survival of renal intrinsic cells. The combination of traditional disease-specific biomarkers and novel serum or urine biomarkers may represent the best choice to correctly classify, stage and treat patients with SLE.<\/jats:p>","DOI":"10.1093\/rheumatology\/keaa484","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T19:14:24Z","timestamp":1595531664000},"page":"v12-v18","source":"Crossref","is-referenced-by-count":55,"title":["New biomarkers in SLE: from bench to bedside"],"prefix":"10.1093","volume":"59","author":[{"given":"Riccardo","family":"Capecchi","sequence":"first","affiliation":[{"name":"Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Puxeddu","sequence":"additional","affiliation":[{"name":"Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pratesi","sequence":"additional","affiliation":[{"name":"Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-4964","authenticated-orcid":false,"given":"Paola","family":"Migliorini","sequence":"additional","affiliation":[{"name":"Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"key":"2020120517370153700_keaa484-B1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"key":"2020120517370153700_keaa484-B2"},{"key":"2020120517370153700_keaa484-B3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.imbio.2015.05.001","article-title":"The paradoxical roles of C1q and C3 in autoimmunity","volume":"221","author":"Scott","year":"2016","journal-title":"Immunobiology"},{"key":"2020120517370153700_keaa484-B4","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1136\/annrheumdis-2014-205287","article-title":"The complement system in systemic lupus erythematosus: an update","volume":"73","author":"Leffler","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020120517370153700_keaa484-B5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020120517370153700_keaa484-B6","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/art.38680","article-title":"Establishment of gene copy number-specific normal ranges for serum C4 and its utility for interpretation in patients with chronically low serum C4 concentrations","volume":"66","author":"Margery-Muir","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370153700_keaa484-B7","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1002\/art.34669","article-title":"Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus","volume":"64","author":"Kalunian","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020120517370153700_keaa484-B8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/art.41093","article-title":"Complement activation in patients with probable systemic lupus erythematosus and ability to predict progression to American College of Rheumatology-classified systemic lupus erythematosus","volume":"72","author":"Ramsey-Goldman","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370153700_keaa484-B9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ab.2015.01.024","article-title":"A quantitative lateral flow assay to detect complement activation in blood","volume":"477","author":"Schramm","year":"2015","journal-title":"Anal Biochem"},{"key":"2020120517370153700_keaa484-B10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.40747","article-title":"Association of blood concentrations of complement split product iC3b and serum C3 with systemic lupus erythematosus disease activity. Version 2","volume":"71","author":"Kim","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370153700_keaa484-B11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/BOR.0b013e3283562c3e","article-title":"Type I IFN system in the development and manifestations of SLE","volume":"24","author":"Elkon","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"2020120517370153700_keaa484-B12","doi-asserted-by":"crossref","first-page":"e000270","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"R\u00f6nnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2020120517370153700_keaa484-B13","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"},{"key":"2020120517370153700_keaa484-B14","doi-asserted-by":"crossref","first-page":"102359","DOI":"10.1016\/j.jaut.2019.102359","article-title":"The pathogenesis of systemic lupus erythematosus: harnessing big data to understand the molecular basis of lupus","volume":"110","author":"Catalina","year":"2020","journal-title":"J Autoimmun"},{"key":"2020120517370153700_keaa484-B15","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1002\/art.24803","article-title":"Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study","volume":"60","author":"Bauer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2020120517370153700_keaa484-B16","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/annrheumdis-2018-213497","article-title":"Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome","volume":"77","author":"van den Hoogen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020120517370153700_keaa484-B17","doi-asserted-by":"crossref","first-page":"e0227069","DOI":"10.1371\/journal.pone.0227069","article-title":"Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus","volume":"15","author":"Matsuoka","year":"2020","journal-title":"PLoS One"},{"key":"2020120517370153700_keaa484-B18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13075-018-1649-1","article-title":"The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus","volume":"20","author":"Oliveira","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2020120517370153700_keaa484-B19","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/rheumatology\/kex220","article-title":"Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study","volume":"56","author":"Rose","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2020120517370153700_keaa484-B20","first-page":"264","article-title":"Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus","volume":"21","author":"Migliorini","year":"2010","journal-title":"Eur Cytokine Netw"},{"key":"2020120517370153700_keaa484-B21","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3389\/fimmu.2018.01250","article-title":"Analysis of serum interleukin (IL)-1\u03b2 and IL-18 in systemic lupus erythematosus","volume":"9","author":"Mende","year":"2018","journal-title":"Front Immunol"},{"key":"2020120517370153700_keaa484-B22","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.autrev.2005.04.009","article-title":"Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18","volume":"4","author":"Calvani","year":"2005","journal-title":"Autoimmun Rev"},{"key":"2020120517370153700_keaa484-B23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13075-018-1525-z","article-title":"IL-1 family cytokines and soluble receptors in systemic lupus erythematosus","volume":"20","author":"Italiani","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2020120517370153700_keaa484-B24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.smim.2013.10.023","article-title":"The interleukin-1 receptor family","volume":"25","author":"Boraschi","year":"2013","journal-title":"Semin Immunol"},{"key":"2020120517370153700_keaa484-B25","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.amjmed.2016.01.013","article-title":"Biomarkers for heart failure: an update for practitioners of internal medicine","volume":"129","author":"Wettersten","year":"2016","journal-title":"Am J Med"},{"key":"2020120517370153700_keaa484-B26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.coi.2015.03.005","article-title":"BAFF receptors and ligands create independent homeostatic niches for B cell subsets","volume":"34","author":"Naradikian","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"2020120517370153700_keaa484-B27","doi-asserted-by":"crossref","first-page":"e000063","DOI":"10.1136\/lupus-2014-000063","article-title":"BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year","volume":"2","author":"Zollars","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2020120517370153700_keaa484-B28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1196\/annals.1313.004","article-title":"BAFF overexpression is associated with autoantibody production in autoimmune diseases","volume":"1050","author":"Pers","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"2020120517370153700_keaa484-B29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/0961203306071871","article-title":"B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time","volume":"15","author":"Becker-Merok","year":"2006","journal-title":"Lupus"},{"key":"2020120517370153700_keaa484-B30","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/rheumatology\/ker282","article-title":"Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study","volume":"50","author":"Eilertsen","year":"2011","journal-title":"Rheumatology (Oxford"},{"key":"2020120517370153700_keaa484-B31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jaut.2018.05.002","article-title":"B-cell activating factor and related genetic variants in lupus related atherosclerosis","volume":"92","author":"Theodorou","year":"2018","journal-title":"J Autoimmun"},{"key":"2020120517370153700_keaa484-B32","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1038\/s41598-020-63390-0","article-title":"Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients","volume":"10","author":"Salazar-Camarena","year":"2020","journal-title":"Sci Rep"},{"key":"2020120517370153700_keaa484-B33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1681\/ASN.2004080658","article-title":"Urine chemokines as biomarkers of human systemic lupus erythematosus activity","volume":"16","author":"Rovin","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2020120517370153700_keaa484-B34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00393-016-0109-z","article-title":"Urinary MCP-1 as a biomarker for lupus nephritis: a meta-analysis","volume":"76","author":"Lee","year":"2017","journal-title":"Z Rheumatol"},{"key":"2020120517370153700_keaa484-B35","doi-asserted-by":"crossref","first-page":"e0343","DOI":"10.1097\/MD.0000000000010343","article-title":"Combined utilization of untimed single urine of MCP-1 and TWEAK as a potential indicator for proteinuria in lupus nephritis: a case-control study","volume":"97","author":"Dong","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2020120517370153700_keaa484-B36","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1177\/0961203318788167","article-title":"Composite urinary biomarkers to predict pathological tubulointerstitial lesions in lupus nephritis","volume":"27","author":"Ding","year":"2018","journal-title":"Lupus"},{"key":"2020120517370153700_keaa484-B37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/eji.201646387","article-title":"Mapping urinary chemokines in human lupus nephritis: potentially redundant pathways recruit CD4+ and CD8+ T cells and macrophages","volume":"47","author":"Klocke","year":"2017","journal-title":"Eur J Immunol"},{"key":"2020120517370153700_keaa484-B38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/annrheumdis-2012-202784","article-title":"Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response","volume":"73","author":"Enghard","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020120517370153700_keaa484-B39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13075-017-1498-3","article-title":"Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis","volume":"20","author":"Mok","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2020120517370153700_keaa484-B40","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41467-020-15986-3","article-title":"Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities","volume":"11","author":"Stanley","year":"2020","journal-title":"Nat Commun"},{"key":"2020120517370153700_keaa484-B41","first-page":"kez528","article-title":"ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus","author":"Parodis","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2020120517370153700_keaa484-B42","doi-asserted-by":"crossref","first-page":"e11287","DOI":"10.1097\/MD.0000000000011287","article-title":"Rapid detection of urinary soluble intercellular adhesion molecule-1 for determination of lupus nephritis activity","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"2020120517370153700_keaa484-B43","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1074\/mcp.M112.021667","article-title":"Urinary angiostatin\u2013a novel putative marker of renal pathology chronicity in lupus nephritis","volume":"12","author":"Wu","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"2020120517370153700_keaa484-B44","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1177\/0961203318804885","article-title":"Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus","volume":"27","author":"Vincent","year":"2018","journal-title":"Lupus"},{"key":"2020120517370153700_keaa484-B45","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/cei.12894","article-title":"Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis","volume":"187","author":"Phatak","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"2020120517370153700_keaa484-B46","doi-asserted-by":"crossref","first-page":"i54","DOI":"10.1093\/ndt\/gft342","article-title":"TWEAK and the progression of renal disease: clinical translation","volume":"29","author":"Sanz","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2020120517370153700_keaa484-B47","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar2816","article-title":"Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study","volume":"11","author":"Schwartz","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2020120517370153700_keaa484-B48","doi-asserted-by":"crossref","first-page":"e000298","DOI":"10.1136\/lupus-2018-000298","article-title":"Urine TWEAK level as a biomarker for early response to treatment in active lupus nephritis: a prospective multicentre study","volume":"6","author":"Suttichet","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2020120517370153700_keaa484-B49","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/art.22008","article-title":"Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus","volume":"54","author":"Brunner","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2020120517370153700_keaa484-B50","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/rheumatology\/kep468","article-title":"Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis","volume":"49","author":"Rubinstein","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2020120517370153700_keaa484-B51","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/art.33485","article-title":"Neutrophil gelatinase-associated lipocalin is instrumental in the pathogenesis of antibody-mediated nephritis in mice","volume":"64","author":"Pawar","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020120517370153700_keaa484-B52","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3899\/jrheum.111470","article-title":"Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis","volume":"39","author":"Kiani","year":"2012","journal-title":"J Rheumatol"},{"key":"2020120517370153700_keaa484-B53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-017-8608-5","article-title":"Could lymphocyte profiling be useful to diagnose systemic autoimmune diseases?","volume":"53","author":"Carvajal Alegria","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2020120517370153700_keaa484-B54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-020-02183-2","article-title":"A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus","volume":"22","author":"Hanaoka","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2020120517370153700_keaa484-B55","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12026-017-8904-4","article-title":"Analysis of FOXP3+ regulatory T cell subpopulations in peripheral blood and tissue of patients with systemic lupus erythematosus","volume":"65","author":"Schmidt","year":"2017","journal-title":"Immunol Res"},{"key":"2020120517370153700_keaa484-B56","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2012-202216","article-title":"Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus","volume":"72","author":"Alexander","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2020120517370153700_keaa484-B57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.21037\/atm.2019.01.38","article-title":"Significant association of CD4+CD25+Foxp3+ regulatory T cells with clinical findings in patients with systemic lupus erythematosus","volume":"7","author":"Yang","year":"2019","journal-title":"Ann Transl Med"},{"key":"2020120517370153700_keaa484-B58","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/cei.13196","article-title":"Facilitated expansion of Th17 cells in lupus nephritis patients","volume":"194","author":"Jakiela","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"2020120517370153700_keaa484-B59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3389\/fimmu.2019.00391","article-title":"Altered Th17\/Treg ratio in peripheral blood of systemic lupus erythematosus but not primary antiphospholipid syndrome","volume":"10","author":"\u00c1lvarez-Rodr\u00edguez","year":"2019","journal-title":"Front Immunol"},{"key":"2020120517370153700_keaa484-B60","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.27385","article-title":"Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity","volume":"62","author":"Crisp\u00edn","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2020120517370153700_keaa484-B61","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0961203319838063","article-title":"CD44v3 and CD44v6 isoforms on T cells are able to discriminate different disease activity degrees and phenotypes in systemic lupus erythematosus patients","volume":"28","author":"Novelli","year":"2019","journal-title":"Lupus"},{"key":"2020120517370153700_keaa484-B62","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s12016-017-8614-7","article-title":"Lymphocytes as biomarkers of therapeutic response in rheumatic autoimmune diseases, is it a realistic goal?","volume":"53","author":"Schreiber","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2020120517370153700_keaa484-B63","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1002\/art.34426","article-title":"Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis","volume":"64","author":"Brunner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020120517370153700_keaa484-B64","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/acs.jproteome.8b00874","article-title":"Discovery and qualification of candidate urinary biomarkers of disease activity in lupus nephritis","volume":"18","author":"Anania","year":"2019","journal-title":"J Proteome Res"},{"key":"2020120517370153700_keaa484-B65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11926-020-00895-7","article-title":"MicroRNA in systemic lupus erythematosus: a perspective on the path from biological discoveries to clinical practice","volume":"22","author":"Hong","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"2020120517370153700_keaa484-B66","doi-asserted-by":"crossref","first-page":"138345","DOI":"10.1172\/jci.insight.138345","article-title":"Accelerating Medicines Partnership in SLE network. Integrated urine proteomics and renal single-cell genomics identify an interferon-\u03b3 response gradient in lupus nephritis","volume":"5","author":"Fava","year":"2020","journal-title":"JCI Insight"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/Supplement_5\/v12\/34729969\/keaa484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/Supplement_5\/v12\/34729969\/keaa484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T22:37:21Z","timestamp":1607207841000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/Supplement_5\/v12\/5903868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":66,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2020,12,5]]},"published-print":{"date-parts":[[2020,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa484","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,12]]}}}